STOCK TITAN

RHYTHM PHARMACEUTICALS (RYTM) SEC Filings, Aug 10-17, 2026

RYTM NASDAQ

Rhythm Pharmaceuticals, Inc.'s SEC filings document a commercial-stage biopharmaceutical company whose disclosures center on IMCIVREE (setmelanotide), MC4R pathway rare-disease indications and related clinical and regulatory milestones. Recent Form 8-K reports include operating results, product-revenue commentary, FDA and European regulatory updates for acquired hypothalamic obesity, and trial disclosures for programs such as TRANSCEND and EMANATE.

Rhythm's proxy materials and governance filings disclose board composition, director elections, executive compensation, equity awards and shareholder voting matters. Other current reports record director changes, Regulation FD materials, presentations and press releases, tying corporate governance and public-company reporting to the company's rare neuroendocrine disease portfolio.

Rhea-AI Summary

RHYTHM PHARMACEUTICALS, INC. executive Joseph Shulman, Chief Technical Officer, exercised 2,024 stock options at an exercise price of $6.80 per share into common stock on 2026-08-13 and sold 5,079 common shares at $119.75 per share. The options, granted on 2022-02-09 and vesting in 16 installments, now show 5,945 options reported as remaining. These transactions were effected under a Rule 10b5-1 trading plan adopted on 2025-12-15.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
insider
-
Rhea-AI Summary

RHYTHM PHARMACEUTICALS, INC. executive Alastair Garfield, Chief Scientific Officer, reported selling a total of 7,763 shares of common stock on August 13, 2026 in four open‑market or private transactions. The sales, made under a Rule 10b5-1 trading plan adopted on May 14, 2026, occurred at weighted average prices of $116.1093, $117.0759, $118.2843, and $119.1688 per share, each representing multiple trades within stated price ranges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
insider
-
Rhea-AI Summary

Rhythm Pharmaceuticals EVP Jennifer Kayden Lee reported multiple transactions in company equity on August 13, 2026. She exercised stock options covering 56,601 shares of common stock at exercise prices of $24.29 and $6.80 per share, receiving the corresponding common shares. She then sold 75,834 shares of common stock at a price of $117.3818 per share. All exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
insider
Rhea-AI Summary

Rhythm Pharmaceuticals EVP Yann Mazabraud exercised stock options to acquire 46,625 shares of common stock at an exercise price of $6.80 per share and reported continuing to hold 35,875 stock options after the exercise. On the same date, he sold an aggregate of 57,000 shares of common stock in multiple open-market transactions at weighted-average prices ranging from approximately $111.58 to $117.60 per share. The exercise and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2026, and the options exercised were part of a grant made on February 9, 2022 that vests in substantially equal quarterly installments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
insider
-
Rhea-AI Summary

RHYTHM PHARMACEUTICALS, INC. (RYTM) officer Alastair Garfield reported a proposed sale of 7,763 common shares, with an aggregate market value of $912,928.80 and an approximate sale date of August 13, 2026. The shares were acquired from the issuer as restricted stock units, with vesting during July 1, 2025 through February 1, 2026. The notice lists May 14, 2026 as the date of plan adoption or giving of instruction, if relying on Rule 10b5-1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
other
-
Rhea-AI Summary

A holder of RYTM common stock filed a notice to sell up to 5,079 shares through Morgan Stanley Smith Barney LLC on or after 08/13/2026 on NASDAQ. The shares relate to an exercise of stock options from 2024 and restricted stock units dated 02/01/2025, with an aggregate market value of $597,290.40.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
other
Rhea-AI Summary

RYTM filed a notice of proposed sale of common stock, to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ. The securities information section lists 75,834 shares, including 56,601 shares tied to an Exercise of Stock Options dated August 13, 2026, and 19,233 shares related to Restricted Stock Units dated February 11, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
other
-
Rhea-AI Summary

Rhythm Pharmaceuticals has a planned sale of 57,000 shares of its common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on August 12, 2026. The shares have an aggregate market value of $6,432,165.00 and are listed on NASDAQ. The sale includes 46,625 shares issuable from the exercise of stock options dated August 12, 2026, and 10,375 shares from restricted stock units dated April 14, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
other
-
Rhea-AI Summary

Rhythm Pharmaceuticals, Inc. (RYTM) common shares are the subject of Pamela Cramer’s proposed sale of 11,406 shares, with an aggregate market value of $1,317,164.88 and an approximate sale date of August 11, 2026. Pamela Cramer is identified as an officer.

Remarks state that the securities to be sold were acquired upon vesting of restricted stock units from July 26, 2022, through July 26, 2024. The notice gives December 15, 2025, as the plan adoption or instruction date under its Rule 10b5-1 entry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
other
Rhea-AI Summary

Rhythm Pharmaceuticals, Inc. (RYTM) officer Pamela Cramer reported a proposed sale of 3,520 common shares, with an aggregate market value of $407,017.60 and an approximate sale date of August 10, 2026. Morgan Stanley Smith Barney LLC is named as the broker.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
other

FAQ

How many RHYTHM PHARMACEUTICALS (RYTM) SEC filings are available on StockTitan?

StockTitan tracks 138 SEC filings for RHYTHM PHARMACEUTICALS (RYTM), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for RHYTHM PHARMACEUTICALS (RYTM)?

The most recent SEC filing for RHYTHM PHARMACEUTICALS (RYTM) was filed on November 17, 2026.